Daymark Wealth Partners LLC Purchases 2,119 Shares of Eli Lilly and Company $LLY

Daymark Wealth Partners LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 18.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,383 shares of the company’s stock after acquiring an additional 2,119 shares during the quarter. Daymark Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $10,211,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Laurel Wealth Advisors LLC raised its holdings in Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $8,827,714,000. Vanguard Group Inc. lifted its holdings in Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after buying an additional 1,183,038 shares during the period. Assenagon Asset Management S.A. boosted its stake in Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after acquiring an additional 765,010 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in Eli Lilly and Company by 13.4% during the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after acquiring an additional 564,736 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 3.6%

NYSE:LLY opened at $1,041.78 on Tuesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. The stock has a 50-day moving average price of $1,017.48 and a two-hundred day moving average price of $853.10. The stock has a market cap of $984.88 billion, a price-to-earnings ratio of 50.97, a PEG ratio of 0.78 and a beta of 0.35. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the previous year, the business posted $1.18 EPS. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is presently 29.35%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and commentary cite Lilly’s long‑term growth setup — strong GLP‑1 franchise, a deep obesity pipeline and AI/innovation tailwinds — that support multi‑year revenue upside and justify bullish ratings. 3 Reasons Why Lilly (LLY) Is a Great Growth Stock
• Positive Sentiment: Several investment writeups highlight Lilly as a top stock for 2026 and note the company’s recent revenue trajectory and guidance, which support longer‑term earnings expectations. 3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
• Neutral Sentiment: Market pieces debate whether now is a buy, hold or sell after a sharp 3‑month gain; these narratives can increase short‑term volatility but don’t change fundamentals immediately. LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
• Neutral Sentiment: Sector/idea pieces list Lilly among AI‑enabled medtech/biotech names to watch — a thematic positive over time but unlikely to drive intraday moves. Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
• Negative Sentiment: Market reaction to Novo Nordisk’s U.S. launch of an oral Wegovy pill is the headline pressure point — investors are pricing in faster share loss and margin competition in the obesity/weight‑loss market. Novo Nordisk Stock Jumps as it Battles Eli Lilly for Market Share with $149 Wegovy Pill Launch
• Negative Sentiment: Legal and political risk intensified as Indiana’s Attorney General filed a lawsuit against Lilly over insulin pricing — this raises potential headline/legal costs and regulatory scrutiny. Indiana sues Eli Lilly over insulin prices
• Negative Sentiment: Short‑term selling pressure is also reflected in quick market checks and opinion pieces suggesting profit‑taking or repositioning after Lilly’s strong run and rising valuation multiples. Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.

Wall Street Analysts Forecast Growth

Several brokerages have commented on LLY. HSBC reiterated a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Scotiabank assumed coverage on Eli Lilly and Company in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price objective for the company. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Loop Capital set a $950.00 target price on Eli Lilly and Company in a research report on Monday, November 10th. Finally, Leerink Partners set a $1,234.00 price target on shares of Eli Lilly and Company in a research report on Monday. Five research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Buy” and an average price target of $1,161.27.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.